These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31657962)

  • 1. Emerging antibiotics for community-acquired pneumonia.
    Liapikou A; Cilloniz C; Palomeque A; Torres T
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):221-231. PubMed ID: 31657962
    [No Abstract]   [Full Text] [Related]  

  • 2. New antibiotics for community-acquired pneumonia.
    Kollef MH; Betthauser KD
    Curr Opin Infect Dis; 2019 Apr; 32(2):169-175. PubMed ID: 30640820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solithromycin for the treatment of community-acquired bacterial pneumonia.
    Viasus D; Ramos O; Ramos L; Simonetti AF; Carratalà J
    Expert Rev Respir Med; 2017 Jan; 11(1):5-12. PubMed ID: 27753516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.
    Donald BJ; Surani S; Deol HS; Mbadugha UJ; Udeani G
    Drug Des Devel Ther; 2017; 11():3559-3566. PubMed ID: 29263651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
    Dillon C; Guarascio AJ; Covvey JR
    Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
    Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.
    Lee YR; Jacobs KL
    Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.
    Amalakuhan B; Echevarria KL; Restrepo MI
    Expert Opin Pharmacother; 2017 Aug; 18(11):1039-1048. PubMed ID: 28598693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
    Watkins RR; File TM
    Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lefamulin (Xenleta) for community-acquired bacterial pneumonia.
    Med Lett Drugs Ther; 2019 Sep; 61(1581):145-148. PubMed ID: 31599865
    [No Abstract]   [Full Text] [Related]  

  • 12. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP).
    Cilloniz C; Torres A
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):569-576. PubMed ID: 37728376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for nosocomial pneumonia.
    Liapikou A; Torres A
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):331-41. PubMed ID: 27347712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
    Chahine EB; Sucher AJ
    Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence.
    Sellarès-Nadal J; Burgos J; Falcó V; Almirante B
    J Exp Pharmacol; 2020; 12():529-538. PubMed ID: 33239925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy for community-acquired pneumonia in the elderly.
    Viasus D; Núñez-Ramos JA; Viloria SA; Carratalà J
    Expert Opin Pharmacother; 2017 Jul; 18(10):957-964. PubMed ID: 28602108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.